Registry Experience at the Washington Hospital Center, DES - Xience V (REWARDS XV)

Rebecca Torguson

Status: Completed

Conditions: Coronary Artery Disease

Study type: Observational

Funder types: Other

Identifiers

NCT01003977

REWARDS XV

Details and patient eligibility

About

Single center registry of patients who have received a Xience V everolimus-eluting stent at the Washington Hospital Center, with the primary objective to assess clinical success and safety at 30 days, 6 months and 1 year post-implantation.

Full description

Interventional cardiology was revolutionized by the invention of stents, initially with the bare-metal stents (BMS) and recently with the drug-eluting stents (DES). The everolimus eluting, Xience V stents have shown very promising results in randomized clinical trials, demonstrating a reduction of clinical and angiographic restenosis in comparison to BMS, and comparable clinically-driven target lesion revascularization rates in comparison with sirolimus-eluting stents. While registry data is available from outside of the United States, it will be important to collect "real-world" data regarding the stent usage and outcomes in the United States. In this study we propose to follow patients who received at least one Xience V® Stent for at least 1 year post initial stent implantation.

Enrollment: 6,069 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients, male or female, >18 years of age
• Patients who received at least one Xience V drug-eluting stent at the Washington Hospital Center

Exclusion criteria

• Patients who received another type of DES (other than Xience V) or a bare metal stent at the time of initial Xience V stent implantation

Trial design

6,069 participants in 1 patient group

Xience V

Description:

Patients treated with a Xience V everolimus-eluting stent